VTRS
Viatris Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$18.97
−1.30%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$19.37
From 52W high−1.30%
Volume11.90M
Market cap$21.79B
P/E (TTM)—
P/S (TTM)1.5x
Div yield1.90%
Key dataNov 5, 2026
Open
$19.37
From 52W high
−1.30%
Volume
11.90M
Market cap
$21.79B
ValuationView details →
P/E (Fwd)
7.2x
EV/EBITDA
12.5x
P/E (TTM)
—
RSI (14)
59.8
MomentumView details →
1D Return
−1.30%
YTD Return
+52.49%
SummaryUpdated Jun 1, 2026
Viatris Inc. (NASDAQ:VTRS) is a global healthcare company formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn division. The company traces its roots back to 1961 and represents one of the world's largest generic and specialty pharmaceutical companies. Headquartered in Canonsburg, Pennsylvania, Viatris operates across more than 165 countries and serves over one billion patients annually with a diverse portfolio of prescription medicines, biosimilars, and active pharmaceutical ingredients.
Similar companies
Latest newsMore news →
Kahn Swick & Foti, LLC said it is investigating the adequacy of the price and process in Pacira BioSciences’ proposed sale to Viatris, under which Pacira shareholders would receive $36.50 per share in cash.8h agoViatris Inc reported quarterly earnings of $0.71 per share, compared with $0.67 per share a year earlier.15h agoViatris reported approximately $300 million in share repurchases through September 30, 2026, and approximately $700 million remaining under its existing board-authorized repurchase program.17h ago